A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Aghajanian, C; Filiaci, VL; Dizon, DS; Carlson, J; Powell, MA; Secord, AA; Tewari, KS; Bender, D; O'Malley, DM; Stuckey, A; Rotmensch, J; Levine, DA; Lankes, HA; Moore, KN

Published Date

  • May 20, 2015

Published In

Volume / Issue

  • 33 / 15_suppl

Start / End Page

  • 5500 - 5500

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2015.33.15_suppl.5500